Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
| Business Activity | PASS |
| Debt Ratio (0.00%) | PASS |
| Cash Ratio (0.11%) | PASS |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-05 | -0.05 | Pending | -- |
| 2026-05-13 | -0.05 | 1.19 | +2270.6% |
| 2026-03-23 | -0.05 | -0.01 | +75.0% |
| 2025-11-13 | -0.05 | -0.06 | -21.8% |
| 2025-08-06 | -0.09 | 0.01 | +115.2% |
| 2025-05-14 | -0.15 | -0.18 | -18.1% |
| 2025-03-27 | -0.12 | -0.10 | +14.5% |
| 2024-11-06 | -0.13 | -0.14 | -6.9% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $179.1M | $169.7M | $169.7M | — | $169.1M | 0.88 |
| 2025-12-31 | $1.1M | -$3.8M | -$3.7M | — | -$7.6M | — |
| 2025-09-30 | $529.0K | -$7.7M | -$7.7M | — | -$8.3M | -0.04 |
| 2025-06-30 | $10.7M | $2.5M | $2.6M | — | $1.9M | 0.01 |
| 2025-03-31 | $1.8M | -$24.5M | -$24.2M | — | -$13.0M | -0.13 |
| 2024-09-30 | — | — | — | — | — | -0.10 |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-02-02 | Androski (Lindsay J.D.) | Senior Officer of Issuer | 28,000 | -- |
| 2026-02-02 | Nguyen (Tuan) | Senior Officer of Issuer | 73,500 | -- |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Morgan Stanley | 25.9M | $112.6M | 0.1% |
| Two Seas Capital Lp | 18.6M | $80.7M | 0.1% |
| Whitefort Capital Management, LP | 14.9M | $64.9M | 0.1% |
| Blackrock Inc. | 13.0M | $56.4M | 0.1% |
| Vanguard Capital Management LLC | 6.7M | $29.1M | 0.0% |
| Rubric Capital Management LP | 6.6M | $28.8M | 0.0% |
| State Street Corporation | 6.3M | $27.6M | 0.0% |
| Barclays Plc | 4.3M | $18.8M | 0.0% |
| Geode Capital Management, LLC | 3.8M | $16.4M | 0.0% |
| Adar1 Capital Management, LLC | 3.1M | $13.6M | 0.0% |
$768.0M
3.29
0.623
3
$191.4M
$3.9M
1.33
8.78
0.1%
19
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.05 | Pending | — |
| 2026-05-13 | $-0.05 | $1.19 | +2270.6% |
| 2026-03-23 | $-0.05 | $-0.01 | +75.0% |
| 2025-11-13 | $-0.05 | $-0.06 | -21.8% |
| 2025-08-06 | $-0.09 | $0.01 | +115.2% |
| 2025-05-14 | $-0.15 | $-0.18 | -18.1% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($5.15, 3 analysts) | |||
| 10 | $42.40 | +$9.10 (21%) | 1.4R |
| 50 | $212.00 | +$45.50 (21%) | 1.4R |
| 100 | $424.00 | +$91.00 (21%) | 1.4R |
- Elevated short interest (8.78 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| HQH | 0.442 |
| IDYA | 0.432 |
| DNLI | 0.411 |
| BETA | 0.410 |
| ARKG | 0.402 |
| Ticker | Correlation |
|---|---|
| USO | -0.175 |
| BNO | -0.171 |
| 4346.SR | -0.138 |
| TAKAFUL.KL | -0.138 |
| ALEC.AE | -0.119 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.